Details for Patent: 12,551,466
Which drugs does patent 12,551,466 protect, and when does it expire?
Patent 12,551,466 protects QLONILIK and is included in one NDA.
Summary for Patent: 12,551,466
| Title: | Ready-to-use oral liquid formulation of clonidine |
| Abstract: | The present disclosure relates generally to a ready-to-use oral liquid formulation of clonidine or pharmaceutically acceptable salt thereof, as well as methods of manufacture and use. |
| Inventor(s): | Manish Umrethia, Ronak Patel |
| Assignee: | Liqmeds Worldwide Ltd |
| Application Number: | US19/307,340 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 12,551,466
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | QLONILIK | clonidine hydrochloride | SOLUTION;ORAL | 221094-001 | Jul 29, 2026 | RX | Yes | Yes | 12,551,466 | ⤷ Start Trial | Y | QLONILIK (CLONIDINE HYDROCHLORIDE) ORAL SOLUTION IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
